Literature DB >> 21969123

Manipulation of nicotinic acetylcholine receptors differentially affects behavioral inhibition in human subjects with and without disordered baseline impulsivity.

Alexandra S Potter1, David J Bucci, Paul A Newhouse.   

Abstract

RATIONALE: Evidence for a relationship between cigarette smoking and attention-deficit/hyperactivity disorder (ADHD) has prompted investigations into nicotinic treatments for this disorder. Impulsivity is a hallmark of ADHD and is measured in the laboratory as behavioral inhibition (BI) using the stop signal task (SST). Acute nicotine improves SST performance in adolescents and young adults who have both ADHD and impaired baseline SST performance, raising questions about the role of nicotinic acetylcholine receptor function in BI. The specificity of this effect to those with ADHD, the component processes of the SST affected by nicotine, and the effects of nicotinic antagonism are yet unknown.
OBJECTIVES: This study investigated the effects of both a nicotinic receptor agonist and antagonist on the SST and choice reaction time task (CRT) in highly impulsive (HI) and control (CTRL) subjects.
METHODS: This was a within-subjects, double-blind study of: 7 mg transdermal nicotine, 20 mg oral mecamylamine, and placebo. Subjects were recruited into HI (n = 11) and CTRL (n = 14) groups based on both SST and clinical criteria.
RESULTS: BI was significantly improved by nicotine compared with placebo in the HI group and impaired by mecamylamine in the CTRL group. Go signal reaction time on the SST was improved by nicotine compared with placebo in the CTRL group and was unchanged in both groups on the CRT.
CONCLUSIONS: These findings demonstrate nicotinic modulation of BI in subjects with both normal and disordered baseline performance. The effects on BI are consistent with cholinergic enhancement of signal detection processes and/or modulation of noradrenaline by nicotine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21969123      PMCID: PMC3288699          DOI: 10.1007/s00213-011-2476-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  74 in total

1.  A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study.

Authors:  Joseph Biederman; Eric Mick; Stephen Faraone; Paul Hammerness; Craig Surman; Theresa Harpold; Meghan Dougherty; Megan Aleardi; Thomas Spencer
Journal:  J Clin Psychopharmacol       Date:  2006-04       Impact factor: 3.153

2.  Deficits in response inhibition associated with chronic methamphetamine abuse.

Authors:  John R Monterosso; Adam R Aron; Xochitl Cordova; Jiansong Xu; Edythe D London
Journal:  Drug Alcohol Depend       Date:  2005-03-31       Impact factor: 4.492

3.  Does methylphenidate improve inhibition and other cognitive abilities in adults with childhood-onset ADHD?

Authors:  A Marije Boonstra; J J Sandra Kooij; Jaap Oosterlaan; Joseph A Sergeant; Jan K Buitelaar
Journal:  J Clin Exp Neuropsychol       Date:  2005-04       Impact factor: 2.475

4.  Cortical and subcortical contributions to Stop signal response inhibition: role of the subthalamic nucleus.

Authors:  Adam R Aron; Russell A Poldrack
Journal:  J Neurosci       Date:  2006-03-01       Impact factor: 6.167

5.  Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults.

Authors:  Scott H Kollins; F Joseph McClernon; Bernard F Fuemmeler
Journal:  Arch Gen Psychiatry       Date:  2005-10

Review 6.  Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review.

Authors:  Erik G Willcutt; Alysa E Doyle; Joel T Nigg; Stephen V Faraone; Bruce F Pennington
Journal:  Biol Psychiatry       Date:  2005-06-01       Impact factor: 13.382

Review 7.  Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization.

Authors:  Edward D Levin; F Joseph McClernon; Amir H Rezvani
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

8.  Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine.

Authors:  E T Tzavara; F P Bymaster; C D Overshiner; R J Davis; K W Perry; M Wolff; D L McKinzie; J M Witkin; G G Nomikos
Journal:  Mol Psychiatry       Date:  2006-02       Impact factor: 15.992

9.  Double dissociation between serotonergic and dopaminergic modulation of medial prefrontal and orbitofrontal cortex during a test of impulsive choice.

Authors:  Catharine A Winstanley; David E H Theobald; Jeffrey W Dalley; Rudolf N Cardinal; Trevor W Robbins
Journal:  Cereb Cortex       Date:  2005-04-13       Impact factor: 5.357

10.  Neurochemical modulation of response inhibition and probabilistic learning in humans.

Authors:  Samuel R Chamberlain; Ulrich Müller; Andrew D Blackwell; Luke Clark; Trevor W Robbins; Barbara J Sahakian
Journal:  Science       Date:  2006-02-10       Impact factor: 47.728

View more
  22 in total

1.  Nicotine Addiction and Psychiatric Disorders.

Authors:  Munir Gunes Kutlu; Vinay Parikh; Thomas J Gould
Journal:  Int Rev Neurobiol       Date:  2015-09-19       Impact factor: 3.230

2.  Effect of varenicline on aspects of inhibitory control in smokers.

Authors:  A J Austin; T Duka; J Rusted; A Jackson
Journal:  Psychopharmacology (Berl)       Date:  2014-03-21       Impact factor: 4.530

3.  Modulation of nicotine effects on selective attention by DRD2 and CHRNA4 gene polymorphisms.

Authors:  Stefan Ahrens; Sebastian Markett; Thomas P K Breckel; Oliver Behler; Martin Reuter; Christiane M Thiel
Journal:  Psychopharmacology (Berl)       Date:  2015-02-03       Impact factor: 4.530

4.  Effects of nicotine on response inhibition and interference control.

Authors:  Ulrich Ettinger; Eliana Faiola; Anna-Maria Kasparbauer; Nadine Petrovsky; Raymond C K Chan; Roman Liepelt; Veena Kumari
Journal:  Psychopharmacology (Berl)       Date:  2017-02-01       Impact factor: 4.530

5.  Haloperidol 2 mg impairs inhibition but not visuospatial attention.

Authors:  H N Alexander Logemann; Koen B E Böcker; Peter K H Deschamps; Peter N van Harten; Jeroen Koning; Chantal Kemner; Zsófia Logemann-Molnár; J Leon Kenemans
Journal:  Psychopharmacology (Berl)       Date:  2016-10-17       Impact factor: 4.530

6.  Detrimental effects of acute nicotine on the response-withholding performance of spontaneously hypertensive and Wistar Kyoto rats.

Authors:  Gabriel J Mazur; Gabriel Wood-Isenberg; Elizabeth Watterson; Federico Sanabria
Journal:  Psychopharmacology (Berl)       Date:  2014-01-11       Impact factor: 4.530

Review 7.  Targeting the nicotinic cholinergic system to treat attention-deficit/hyperactivity disorder: rationale and progress to date.

Authors:  Alexandra S Potter; Geoffrey Schaubhut; Megan Shipman
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 8.  Attention-deficit/hyperactivity disorder and adverse health outcomes.

Authors:  Joel T Nigg
Journal:  Clin Psychol Rev       Date:  2012-12-07

9.  Rate dependent effects of acute nicotine on risk taking in young adults are not related to ADHD diagnosis.

Authors:  Katherine K Ryan; Sarahjane L Dube; Alexandra S Potter
Journal:  Pharmacol Biochem Behav       Date:  2012-11-15       Impact factor: 3.533

Review 10.  Potential therapeutic uses of mecamylamine and its stereoisomers.

Authors:  Justin R Nickell; Vladimir P Grinevich; Kiran B Siripurapu; Andrew M Smith; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2013-04-18       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.